Assessment of Serum and Tissue Tryptase Levels in Acne Vulgaris Patients - Trial NCT06158061
Access comprehensive clinical trial information for NCT06158061 through Pure Global AI's free database. This phase not specified trial is sponsored by Sohag University and is currently Not yet recruiting. The study focuses on Acne Vulgaris. Target enrollment is 90 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sohag University
Timeline & Enrollment
N/A
Jan 24, 2024
Aug 15, 2024
Primary Outcome
serum tryptase level,tissue tryptase level
Summary
Acne vulgaris is an inflammatory disorder of pilosebaceous glands. Acne is a highly prevalent
 inflammatory disease affecting approximately 9.4% of the world's population , and estimated
 up to 90% among adolescents. By natural course acne starts at 7-12 ages and mostly resolves
 by the third decade of individuals life .
 
 Mast cells may play important role in maintenance of physiological functions of our body;
 they also have a role in pathological and inflammatory mechanisms of many diseases. Tryptase
 is suggested to be important for survival as no tryptase-deficient human subject has yet been
 reported. Tryptase is mainly synthesized by mast cells but a very low amount may originate in
 basophil with no interference with total levels of the enzyme. Tryptase is currently
 considered as a metabolic signaling and effector mediator for acute mast cell degranulation
 and late phase of allergy and inflammation .
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06158061
Non-Device Trial